.. Adalimumab may be viable treatment choice for patients with refractory pediatric uveitis A fresh study published in today’s problem of the Journal of the American Association for Pediatric Ophthalmology and Strabismus shows that the biologic agent adalimumab may be a viable treatment option for sufferers with steroid-resistant refractory pediatric uveitis. In a scholarly study of fifteen children with the condition 85.7 percent showed preliminary improvement of anterior/posterior chamber inflammatory activity after almost three months of treatment., Seat of AHF’s Panel of Directors. The AHF group fulfilled with Kevin De Cock, M.D. , Director of the WHO HIV/AIDS Department, Ying-Ru Lo, M.D. , Coordinator, Prevention in medical Sector, Division of F and HIV/AIDS. Amolo Okero , Technical Officer, Section of HIV/Helps. Present at the UNAIDS conference were Barbara de Zalduondo , Chief of Programmatic Priorities Support, Evidence, Monitoring and Policy Department; Michael Bartos , Chief, Prevention, Support and Treatment and Karusa Kiragu , Senior Avoidance Advisor. ‘AHF appreciates this possibility to talk with representatives from WHO and UNAIDS and we are pleased that our concerns regarding the need for updated treatment recommendations and fresh HIV testing and avoidance models are being heard,’ said Dr.